Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Evocumab plus statins vs statins alone after PCI
ChiCTR2300070824Phase 4Not yet recruiting
- Sponsor
- The Second Affiliated Hospital of Dalian Medical University
- Start
- Apr 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, randomised trial of evolocumab in coronary arteriosclerosis (2 arms), sponsored by The Second Affiliated Hospital of Dalian Medical University. Primary endpoint: Percent atheroma volume (PAV) at 8 weeks. Planned start Apr 2023; status: not yet recruiting.
02
Drugs
evolocumab
03
Conditions
coronary arteriosclerosis
Beyond the preview
Go deeper on ChiCTR2300070824.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300070824.